Align Technology's (ALGN) stock performance has been fluctuating significantly, with repeated gains and losses in recent periods. The anticipated
Q2 2024 Earnings Call report indicates a reduced sales view for '24, which shows the company is currently underperforming in the market. Notably,
brokerage firms have recommended 'Moderate Buy'. ALGN has shown unusual options activity and unveiled their
iTero™ Design Suite, aimed at boosting clinical efficiency. Despite decreased profits, Q2 earnings have topped estimates. However, several investors and brokerage firms have
lowered their price target for ALGN after the company cut its revenue forecast for 2024. Nevertheless, multiple agencies have increased their stake in ALGN, indicating sustained interest.
Align's EPS has risen in Q2 2024. Despite
ratings downgrade the stock is still considered a 'buy'. Recent strategic decisions include a
$150M repurchase program, as well as the appointment of Emory Wright to head up next-generation manufacturing operations.
Align Technology ALGN News Analytics from Fri, 27 Oct 2023 07:00:00 GMT to Sun, 28 Jul 2024 17:07:41 GMT -
Rating -3
- Innovation 3
- Information 6
- Rumor -4
